Legendary Investments discovers large gold-antimony
AIM-listed investment company Legendary Investments' investee company, Medgold Resources Corporation has completed exploration at its wholly-owned Pietratonda licence in the Colline Metallifere of Central Italy.
AIM-listed investment company Legendary Investments' investee company, Medgold Resources Corporation has completed exploration at its wholly-owned Pietratonda licence in the Colline Metallifere of Central Italy.
The company reported that a total of 273 rock samples had been collected and a large gold-antimony anomaly had been outlined.
Antimony is a silvery-grey chemical element which occurs naturally in nature as a solid compound with sulphur.
Subscribe to MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE

Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
The company added that clear drill targets had additionally been defined, which were designed to test mineralisation at depth.
Zafar Karim, Executive Chairman of Legendary Investments, commented: "Medgold's momentum continues to build and it remains on track towards its stated ambition to be the leading Mediterranean-focused gold exploration and project development company. We look forward to further progress."
Legendary Investments' share price was up 13.33% to 0.08p at 09:20 on Friday.
MF
-
December 2023 NS&I Premium Bond winners - check now to see what you’ve won
If you hold money in NS&I Premium Bonds, you can check from today (2 December) to see if you have won in the December prize draw. Here’s how to check.
By Vaishali Varu Published
-
OpenAI – corporate drama unleashed
OpenAI, the firm behind ChatGPT, was in uproar as its boss was booted out, briefly snapped up by Microsoft and then brought back again.
By Dr Matthew Partridge Published